Johnson & Johnson: Talvey and Darzalex Fastro Based Combination Shows Deep and Durable Responses in Patients With Relapsed or Refractory Multiple Myeloma
September 28, 2024
September 28, 2024
NEW BRUNSWICK, New Jersey, Sept. 28 (TNSres) -- Johnson and Johnson issued the following news release:
* * *
Updated data show 100 percent overall response rate with 56 percent of patients achieving complete response or better with weekly dosing, supporting the combinability of the GPRC5D bispecific antibody
Safety profile, including infection rates, similar to TALVEY and DARZALEX FASPRO monotherapies
* * *
RIO DE JANEIRO (Septembe . . .
* * *
Updated data show 100 percent overall response rate with 56 percent of patients achieving complete response or better with weekly dosing, supporting the combinability of the GPRC5D bispecific antibody
Safety profile, including infection rates, similar to TALVEY and DARZALEX FASPRO monotherapies
* * *
RIO DE JANEIRO (Septembe . . .